nasal type
Showing 1 - 25 of >10,000
Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))
Active, not recruiting
- Extranodal NK/T Cell Lymphoma, Nasal Type
- IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
-
Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 10, 2022
Type 1 Diabetes, Diabetes, Type 1 Trial in Australia (Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®), Abatacept (CTLA4-Ig)
Recruiting
- Type 1 Diabetes
- Diabetes Mellitus, Type 1
- Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)
- Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)
-
Westmead, New South Wales, Australia
- +5 more
Feb 15, 2023
Chronic Rhinosinusitis With Nasal Polyps Trial in Kafrelsheikh (Budesonide, Prednisone, Saline)
Completed
- Chronic Rhinosinusitis With Nasal Polyps
- Budesonide
- +2 more
-
Kafrelsheikh, EgyptKafrelsheikh University hospital
Jul 3, 2023
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,
Recruiting
- Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
- +2 more
- Anti-PD-1 monoclonal antibody
- +4 more
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022
Hypoglycemia Unawareness, Type 1 Diabetes Trial in Minneapolis (intra-nasal naloxone, Intra-nasal saline)
Terminated
- Hypoglycemia Unawareness
- Type 1 Diabetes
- intra-nasal naloxone
- Intra-nasal saline
-
Minneapolis, MinnesotaClinical and Translational Science Institute, University of Minn
Sep 26, 2022
Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)
Recruiting
- Early-stage
- Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
- Anti-PD-1 monoclonal antibody
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Dec 7, 2021
Efficiency of HFNC Vs NIV in Patient With Acute Type 2 RF
Completed
- Type 2 Respiratory Failure
-
Banī Suwayf, Bani Suwayf, EgyptFaculty of medicine
Jan 22, 2023
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)
Completed
- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
- +7 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Jun 6, 2022
Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Shanghai (Methotrexate, Etoposide, Dexamethasone)
Active, not recruiting
- Extranodal NK/T-cell Lymphoma, Nasal Type
- Methotrexate
- +4 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Aug 19, 2021
Central Insulin Resistance, Diabetes, Type 2, PreDiabetes Trial (Human nasal insulin, Placebo)
Not yet recruiting
- Central Insulin Resistance
- +2 more
- Human nasal insulin
- Placebo
- (no location specified)
May 12, 2023
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Trial in Shanghai (Anlotinib)
Completed
- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
-
Shanghai, ChinaXinhua Hospital
Sep 13, 2021
Viral and Epigenetic Influences in CRSwNP
Recruiting
- Chronic Rhinosinusitis (Diagnosis)
- Endoscopic sinus surgery (ESS)
-
Montréal, Quebec, CanadaCHUM
May 19, 2023
COVID-19, Influenza A, Influenza Type B Trial in Nashville (Panbio™)
Recruiting
- COVID-19
- +2 more
- Panbio™
-
Nashville, TennesseeUCCT @ Complete Health Partners- Nashville
Dec 21, 2022
Type 1 Diabetes Trial in United States (Glucagon Nasal Powder [Baqsimi])
Recruiting
- Type 1 Diabetes
- Glucagon Nasal Powder [Baqsimi]
-
Los Angeles, California
- +8 more
Apr 6, 2022
Chronic Disease, Nasal Polyposis, Rhinitis Trial in Trondheim (botox injection Multiguide)
Completed
- Chronic Disease
- +2 more
- botox injection Multiguide
-
Trondheim, NorwaySt Olavs Hospital
Oct 29, 2021
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)
Recruiting
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Classical Hodgkin Lymphoma
- CD30.CAR-EBVST cells
-
Houston, Texas
- +1 more
Jul 20, 2022
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Trial in Shanghai (tislelizumab, azacytidine, lenalidomide, tislelizumab,
Recruiting
- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
- tislelizumab, azacytidine, lenalidomide
- tislelizumab, etoposide, pegaspargase
-
Shanghai, Shanghai, ChinaXinhua Hospital,Shanghai Jiao Tong University School of Medicine
Sep 17, 2021
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by
Not yet recruiting
- Adult T-cell Leukemia/Lymphoma
- +4 more
- CC-486 (5-azacitidine)
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Lymphoma Trial in Philadelphia (Pembrolizumab)
Withdrawn
- Lymphoma
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
May 5, 2021
Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)
Completed
- Peripheral T Cell Lymphoma
- +18 more
-
Vancouver, British Columbia, Canada
- +29 more
Apr 29, 2022
Sialolithiasis Trial in Seoul (nasotracheal tube (Ring-Adair-Elwin), nasotracheal tube (portex))
Recruiting
- Sialolithiasis
- nasotracheal tube (Ring-Adair-Elwin)
- nasotracheal tube (portex)
-
Seoul, Korea, Republic ofGangnam Severance Hospital
Mar 16, 2022
Diabetes, Type 1, Hypoglycemia, Hypoglycemia Unawareness Trial in Bronx (Naloxone, Diazoxide, Placebo (for Naloxone))
Suspended
- Diabetes Mellitus, Type 1
- +2 more
- Naloxone
- +3 more
-
Bronx, New YorkAlbert Einstein College of Medicine
Feb 3, 2022
COVID-19, Influenza A, Influenza Type B Trial in Easley (Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B
Recruiting
- COVID-19
- +2 more
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
-
Easley, South CarolinaUrgent Care Clinical Trials Easley
Apr 28, 2022
Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Not yet recruiting
- Lymphoma
- +8 more
- No interventions need to be specified for this study
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023